cyrilzakka/clinical-trials huggingface dataset:
Integrative Medicine for Chronic Pain

In this study, the effects of a 14-day inpatient treatment in an internal medicine ward for integrative medicine on pain, disability, quality of life, satisfaction with life, depression, and anxiety will be investigated. Furthermore the influence of potential process variables will be evaluated.

Effects will be measured after completion of the program (2 weeks), and at 6 months follow up after start of the program.


Eligibility Criteria:
Inclusion Criteria:

* diagnosed with any chronic pain condition
* at least 6 months pain duration
* written informed consent

Exclusion Criteria:

* participation in any other clinical study
35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Inflammation of Skin

To explore the clinical effect and safety of 35 kDa hyaluronic acid fragment ( HA35 ) combined with negative pressure microneedle technology in improving skin problems.


Eligibility Criteria:
Inclusion Criteria:

* Skin problems include but are not limited to dry skin, dark skin, and coarse pores.
* Chronic skin inflammation, pigmentation, erythema, etc.
* Cooperate with the experimental requirements and be able to complete the score independently。

Exclusion Criteria:

* Pregnant or lactating women.
* Suffering from psychological or mental illness.
* Life is not regular, overeating.
* Hypersensitive to hyaluronic acid, and has a scar constitution.
Effect of His-Ventricular (HV) Interval Optimisation in Cardiac Resynchronisation Therapy

Cardiac resynchronisation therapy (CRT) is a specialised type of pacemaker used in patients with severe heart failure to improve symptoms and survival. Approximately one third of patients treated with CRT do not notice significant improvement in their symptoms and this may be due to inadequate co-ordination between the upper and lower chambers of the heart (atrioventricular dyssynchrony).

The investigators propose a new method to achieve atrioventricular synchrony in CRT based on measurements of electrical conduction from within the heart. Patients referred for CRT implantation at Castle Hill Hospital are eligible to participate. During CRT implantation, additional measurements, will be recorded from within the heart. After implantation, device settings will be adjusted to either standard or electrophysiologically-optimised settings with cross-over at 4 months.

The investigators hypothesis is that patients with optimised settings will derive additional benefit compared to patients with standard pacemaker-determined settings.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of heart failure
* Referred for cardiac resynchronisation therapy (CRT) with or without defibrillator
* In sinus rhythm
* Patients must have a telephone
* Ability to give informed consent
* Ability to complete the study

Exclusion Criteria:

* Severe valve disease or previous valve replacement
* Previous atrial flutter ablation
* Chronic kidney disease Stage 3 or above
* Recent myocardial infarction
* Ongoing cardiac ischaemia
* Infiltrative cardiomyopathy
* Wolff-Parkinson White syndrome
* Presence of second or third degree heart block
* \<90% biventricular pacing at 3 months
* Hypertrophic cardiomyopathy
* Pregnancy or breastfeeding
* On treatment for hypothyroidism or hyperthyroidism
Sleep Plus Eating Routines for Weight Loss

The present study will test the effectiveness of two different approaches for preparing overweight/obese individuals for weight loss: 1)providing important information about weight control, including dispelling common myths; or 2) developing a consistent sleep and eating routine to prepare for the challenges of a weight control intervention.


Eligibility Criteria:
Inclusion Criteria:

* age 21 to 65
* BMI 25 to 45
* sleep 7 hours or less most nights

Exclusion Criteria:

* use of medications affecting sleep
* sleep apnea
* shift work
Effect of Kinetic Control Training on Flexion Relaxation Phenomenon and Craniovertebral Angle in Cervical Radiculopathy Patients

The purpose of the study is to determine the effect of kinetic control training on flexion relaxation phenomenon and craniovertebral angle in patients with cervical radiculopathy.

Neck pain is a major health issue with high rates of recurrence. The current literature suggests people with cervical pain have altered movement control strategies and that these changes are associated with pain and disability.

These altered strategies will influence the control of movement which can present as both uncontrolled translatatory movement and uncontrolled range or physiological motion. Either movement dysfunction will present clinically as areas of relative flexibility (increase in translational movement) or areas of relative stiffness.

Changes in alignment in the cervical spine may result in a forward head posture position demonstrating an increase in low cervical flexion.

The greater the forward head posture, the greater the disability. Regions and segments of less mobility have been noted in the cervical spine which will present clinically as regions of relative stiffness.

Disturbance in neck flexor synergy has been commonly observed in patients with neck pain. This disturbed neck flexor synergy presents as altered pattern of muscle activity, where impairment in deep cervical flexors appears to be compensated by increased activity in superficial muscles (sternocleidomastoid and anterior scalene) and it is also reported that the amplitude of upper trapezius and cervical extensors have been dramatically increased among those patients. Such impairments may contribute to the development of pain and disability in patients with neck pain.

The Kinetic Control retraining strategy consists of patient education about his uncontrolled movement, retraining the coordination of movement direction control and muscle synergy retraining. Movement retraining interventions that are matched to correcting specific impairments can restore movement and performance solutions, elevating movement health and the quality of life it supports.

Eligibility Criteria:
Inclusion Criteria:

1. Patients will be referred from neurologist with the diagnosis cervical spondylosis.
2. Patients will be included if they have unilateral radiculopathy due to spondylotic changes of the lower cervical spine (C5-C6 and C6-C7).
3. Duration of symptoms is more than three months to avoid acute stage of inflammation.
4. Patient's age ranged from 40 to 55 years.
5. Patients from both sexes.
6. Body mass index of all patients is ranged from 25-30 kg/m2.
7. Patients will be screened prior to inclusion by measuring the craniovertebral angle, if the angle was less than 50, then a participant will be referred to the study

Exclusion Criteria:

1. Spinal canal stenosis.
2. Rheumatoid arthritis.
3. Vertebrobasilar insufficiency.
4. Spinal instability due to structural cause e.g., spondylolisthesis.
5. Systemic disease (cardiovascular, infectious and/or metabolic disease that could interrupt exercises).
6. Spinal tumors.
Effect of Finger Feeding

With the planned study, it was aimed to determine the effect of finger feeding method on newborns in term babies.

It was planned as a randomized controlled experimental study design.

Full randomization will be performed and infants who meet the inclusion criteria will be assigned to groups by flipping a coin.

On the toss of a coin, if heads came up then subject was allocated to the control group. If tails came up, then subject was allocated to the intervention group. This procedure was repeated for each mother.

Within the scope of the study, "Informed consent" will be obtained from the parents for infants who need formula supplementation or for infants fed with expressed breast milk by the decision of the Physician in the experimental and control groups.

Babies in the control group will continue to receive routine care and no intervention will be made on their feeding style. The researcher will be informed verbally and practically about the finger feeding method and the application steps to the mothers of the babies in the experimental group and to the family members who will support their feeding in baby care. In this direction, it will be ensured that expressed breast milk or formula support is given by finger feeding method.

Eligibility Criteria:
Inclusion Criteria:

Mother is 18 years or older Newborns 38 weeks and older Newborns who do not have any postnatal health problems and are followed up with the mother Babies taking formula supplements Babies who have difficulty breastfeeding There is no obstacle to breastfeeding or breastfeeding

Exclusion Criteria:

Babies with sucking and swallowing dysfunction Babies with respiratory distress (respiratory rate over 60/min, babies with groaning, nasal wing breathing)

-
Optimal Anesthetic for Corticosteroid Injections for Knee Osteoarthritis

To evaluate pain relief from corticosteroid injection with and without anesthetic as well as with variable volume of anesthetic. Pain relief will be measured using the VAS pain score at the time of the injection as well as several time points following the injection to capture pain relief longevity. The investigators intend to evaluate how well the patients tolerate corticosteroid mixtures without anesthetic as well as with different volumes of anesthetic. Primary measure will be the time from procedure when postoperative status is considered success (as measured by global perceived improvement score).

Primary objective is to evaluate pain relief from corticosteroids, Kenalog without anesthetic as well as with different volumes of anesthetic. The investigators will measure the VAS pain score at the time of the injection as well as several time points following the injection. Additionally, the investigators will evaluate how long the injection provided pain relief for the patient.

The secondary intend is to evaluate how well the patients tolerate Kenalog mixtures without anesthetic as well as with different volumes of anesthetic by using the VAS pain scale.

The investigators hypothesize that patient with lower volume of injection will experience less pain during the procedure and that there will be no statistically significant difference in pain level between the study groups during the study period.

Eligibility Criteria:
Inclusion Criteria:

1. Patients must be 18 years of age and be able to consent for themselves.
2. OA grade Kellgren Lawrence Stage II or III.
3. Diagnosis of primary osteoarthritis.

Exclusion Criteria:

1. Patients with other forms of arthritis such as inflammatory arthritis.
2. History of narcotic use for the past 6 months.
3. Kellgren Lawrence arthritis grade 1 or 4.
4. Pregnant women and prisoners.
A Multifaceted Prompting Intervention for Urban Children With Asthma

The overall goal of this project is to evaluate whether a multifaceted prompting intervention, administered in the urban primary care office setting, reduces morbidity among urban children with asthma. This study builds on our experience with a pilot study in two urban continuity clinics, in which we found that prompting clinicians about asthma severity and care guidelines at the time of an office visit resulted in improved preventive care delivery to inner-city children. This type of prompting program has the potential to substantially improve care for impoverished children with asthma, and we propose to establish: 1) whether these findings can be replicated in a similar study including a larger sample of urban children from different types of practices, and 2) whether the positive effects can be enhanced by more specific prompting directed towards both the provider and the caregiver and by providing practice-level supports and feedback. We hypothesize that children receiving a multifaceted prompting intervention (MPI) will experience less asthma-related morbidity (defined by symptom-free days at the 2-month follow-up) compared to children receiving usual care. Our secondary hypothesis is that children receiving the MPI will receive improved preventive asthma care (defined by guideline-based corrective actions taken at the index visit) compared to children receiving usual care.


Eligibility Criteria:
Inclusion Criteria:

* Physician-diagnosed asthma
* Mild persistent or more severe asthma severity, or poor asthma control
* Age \>2 and \<12 years.
* Parent or caregiver must give permission to the study, and children \>7 will must provide assent.

Exclusion Criteria:

* Inability to speak and understand English or Spanish
* No access to a working phone for follow-up surveys
* The child having other significant medical conditions,
* Children in foster care or other situations in which consent cannot be obtained from a guardian.
* Prior enrollment in the study.
* Child will not be seen by a physician or nurse practitioner during their visit
Avoiding Hypotension in Preterm Neonates

Objectives Firstly to examine in preterm neonates, whether it is possible to reduce number of hypotensive episodes and use of catecholamines by applying cerebral/peripheral near infrared spectroscopy in combination with predefined interventions and secondly to explore the potential impact on cerebral injury and mortality.

Hypothesis By using predefined interventions for changes in cerebral/peripheral oxygenation ratio investigators will reduce hypotensive episodes and use of catecholamines which will reduce cerebral injury and mortality.

Methods Cerebral (cTOI) and peripheral-muscle (pTOI) tissue-oxygenation-index (NIRO 300) will be measured for 24h starting \<6 hours postpartum. When cTOI/pTOI ratio increases \>5% within a 6h period, predefined interventions will be performed.

Primary outcome parameter will be duration of hypotensive episodes and use of catecholamines during the first 48h after birth. Secondary outcome parameters will be cerebral injury and mortality.


Eligibility Criteria:
Inclusion Criteria:

* preterm neonates
* decision to conduct full life support
* written informed consent
* age \<6 hours
* no use of catecholamines before start of NIRS measurements

Exclusion Criteria:

* no decision to conduct full life support
* no written informed consent
* age \>6 hours
* use of catecholamines before start of NIRS measurements
* congenital malformation
Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study

This is a prospective biomedical study of interventional type which includes 16 patients on 52 months (24 months of inclusion and 28 months of follow up).

This pilot study, combining a metabolic imaging approach (Proton Magnetic Resonance Spectroscopy = 1HMRSI) and a biological one, will be performed in patients harbouring a Glioblastoma (GBM)to determine whether MRI markers of aggressiveness (CNI2) are associated with specific biological patterns as regards to GBMSC (GBM contains tumor stem cell).

In the first part of the study, patients with radiological criteria of GBM amenable to surgical resection will be included ; pre-operative multimodal MRI scans will be done and all data acquired (including H1MRS and DTI data) will be integrated in the image-guided surgical device (ie neuronavigation system) to be used intraoperatively. During tumor resection, tissue samples will be individualized, based on their multimodal imaging characteristics and sent to the radiobiology laboratory INSERM for biological analysis.

After surgery, patient will be treated by the standard radio-chemotherapy stupp protocol and will be followed according to standard practices; multimodal MRI will be performed every 2 months during the first year and then every 3 months until progression.


Eligibility Criteria:
Inclusion Criteria:

First part of the study (Surgery and Imagery):

1. Surgical indication for patients who present radiological criteria of glioblastoma.
2. Patient who are ≥18 years old
3. Patient must have performance status between 0 and 2 on the ECOG Performance Scale
4. Life expectancy ≥ 3 months
5. Patient affiliated to social security regimen
6. Patient has voluntarily agreed to participate by giving written informed consent for the first part of the study.

Second part of the study (Treatment and Biology):

1. Histologically confirmed glioblastoma
2. Patient must have performance status between 0 and 2 on the ECOG Performance Scale or 3 only is due to motor deficit.
3. Life expectancy ≥ 3 months
4. Patient affiliated to social security regimen
5. Patient has voluntarily agreed to participate by giving written informed consent for the second part of the study.

Exclusion Criteria:

First part of the study (Surgery and Imagery):

1. Patients who are not allowed to perform an MRI
2. Spectroscopic exam whose results are not contributive
3. Pregnant or nursing patient,
4. Patients under law protection
5. Patient who presents conditions that would interfere with cooperation with the requirements of the trial.
6. Patient who presents medical, severe or chronic biological or psychiatric conditions not allowing his enrolment in the study, according to the investigator's opinion

Second part of the study (Treatment and Biology):

1.Biological material received in the lab more than 48 hours after surgery.
Low-Dose Versus High-Dose Oxytocin Dosing for Induction and Augmentation of Labor

The goal of this clinical trial is to compare oxytocin infusion rates for induction and augmentation of labor in nulliparous women. The main question\[s\] it aims to answer are:

* Does a high dose oxytocin infusion protocol affect length of induction to delivery interval?
* Does a high dose oxytocin infusion protocol affect mode of delivery?
* Does a high dose oxytocin infusion protocol affect maternal and neonatal outcomes?

Participants will be randomized to either low- or high-dose oxytocin groups:

* The low dose group will receive an infusion to start at 2 milli-units/min and will be increased by 2 milli-units/min every 20 minutes. The maximum rate of infusion is 40 milli-units/min.
* The high dose group will receive an infusion to start at 6 milli-units/min and will be increased by 6 milli-units/min every 20 minutes. Maximum rate of infusion is 40 milli-units/min.


Eligibility Criteria:
Inclusion Criteria:

* Women aged 18-50 years old
* Singleton gestation
* Nulliparous
* Vertex presentation
* Gestational age greater than or equal to 37 weeks
* No prior uterine surgery
* Presents for elective or medically indicated induction of labor
* Need for augmentation of labor with oxytocin

Exclusion Criteria:

* Previous cervical ripening using non-mechanical methods
* Patient unable or unwilling to provide verbal consent
* Contraindications to vaginal delivery
* Fetal demise or life-limiting anomaly
* Allergy to oxytocin
* Non-reassuring fetal heart tracing prior to inclusion
* Maternal pulmonary edema prior to inclusion
* Fetal growth restriction
The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients

To evaluate the safety and tolerance of topical cidofovir (HPMPC) therapy for condyloma acuminatum in patients with HIV infection. To investigate whether topical HPMPC therapy can induce regression of condyloma acuminatum in patients with HIV infection.

Four groups of 10 patients each receive topical HPMPC at 0.3 percent concentration for 5 or 10 days total or 1.0 percent concentration for 5 or 10 days total, followed by 2 weeks of rest. When six patients at a given dose and schedule have completed treatment and follow-up without significant toxicity, subsequent patients are entered at the next higher dose level. Patients are evaluated twice weekly during treatment and once weekly during the rest period. HPMPC may be extended for up to two additional courses in patients who experience no significant toxicity.

Eligibility Criteria:
Inclusion Criteria

Concurrent Medication:

Allowed:

* AZT, ddI, ddC, d4T, or 3TC.
* Oral trimethoprim/sulfamethoxazole.
* Aerosolized pentamidine.
* Dapsone.
* Fluconazole.
* Rifabutin.
* Clarithromycin.

Patients must have:

* HIV seropositivity.
* Mean CD4 count \>= 100 cells/mm3.
* External anogenital condyloma acuminatum confirmed by biopsy, present for less than 1 year. NOTE:
* Warts on anal, urethral, or vaginal mucosa will not be studied.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Active lesions of genital herpes, other skin wounds, or active inflammatory skin disorders in the same area as warts to be treated.
* Active medical problems sufficient to hinder study compliance.

Concurrent Medication:

Excluded:

* Podofilox or any podophyllum resin preparation.
* Liquid nitrogen treatment.
* Interferon alpha.
* Trichloracetic acid.
* Other treatments, topical or systemic, surgical or ablative, known to have anti-papilloma activity.
* Other investigative drugs (except d4T or 3TC) unless approved by the sponsor.

Patients with the following prior conditions are excluded:

History of untreated syphilis or Bowenoid papulosis.

Prior Medication:

Excluded within 4 weeks prior to study entry:

* Treatment for anogenital warts.
* Immunomodulators (including interferons or systemic corticosteroids).
* Lymphocyte replacement therapy.
* Biologic response modifiers. Substance abuse.
Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)

Liver transplantation (LT) is a high-risk surgery for hemodynamic instability and haemorrhagic shock with a high-risk of acute kidney injury (AKI). Indeed, the incidence of post-transplant AKI exceeds 50% in some series with 15% of patients requiring renal replacement therapy. Acute kidney injury after LT is a predisposing factor for chronic renal failure which is independently associated with higher morbidity and mortality.

Arginine vasopressin (AVP), an essential stress hormone released in response to hypotension, binds to AVPR1a to promote vasoconstriction. Furthermore, it may have nephroprotective effects with a preferential vasoconstriction of the post-glomerular arteriole resulting in increased glomerular filtration

The hypothesis of the present work is that low-dose arginine-vasopressin supplementation reduce posttransplant AKI in liver transplantation.

Prospective, national multicenter, double-blinded, randomized , controlled superiority trial with two parallel arms : AVP vs Norepinephrine

The primary objective is to demonstrate that intraoperative low-dose supplementation of AVP induces a reduction in posttransplant AKI after liver transplantation

Investigational medicinal product: vasopressin will be administered by continuous infusion. AVP will be used to a final concentration of 0.12 U/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that AVP doses ranged from 0.01 to 0.06 U/min.

Comparator treatment : norepinephrine will be administered by continuous infusion. Norepinephrine will be used with final concentrations of 120 microg/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that NE doses ranged from10 to 60 microg/min.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* Any adult patient with a scheduled liver transplantation
* All participants will need to be given clear information about the study and give signed informed consent.
* Person affiliated to the Social Security

Exclusion Criteria:

* Super-emergency for liver transplantation or fulminant hepatitis
* Patient listed for or receiving simultaneous liver-kidney transplantation (SLKT)
* Patients with end-stage renal disease (chronic eGFR \< 15 mL/min/1.73 m2 or requiring extra-renal purification before liver transplantation
* Patient with epilepsy
* Hypersensitivity to arginine-vasopressin and to its excipients
* Patient refusal
* Patients for whom it is impossible to give informed consent (language barrier)
* Adults under guardianship or trusteeship, persons deprived of their liberty
* Patient enrolled in another interventional clinical study
* Pregnancy or breastfeeding